CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 8.12: safe zone
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.30%
Annual Rate
CNY 0.13Paid unknown
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
Jul 13, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.29BCNY489.50M · vs all stocks (USD)
Trailing P/E
105.20xvs Biotechnology peers
Revenue (TTM)
432.55MCNY64.32M · vs all stocks (USD)
Profit Margin
7.65%vs Biotechnology peers
Beta
0.3300xvs all stocks
52-Week Change
-28.97%vs all stocks
Forward Annual Dividend Yield
0.30%vs all stocks
Market Capitalization
3.29BCNY489.50M · vs all stocks (USD)
Enterprise Value
2.26BCNY336.06M · vs all stocks (USD)
Trailing P/E
105.20xvs Biotechnology peers
Price to Sales (TTM)
8.34xvs Biotechnology peers
Price to Book (MRQ)
2.04xvs Biotechnology peers
Enterprise to Revenue
5.22xvs Biotechnology peers
Enterprise to EBITDA
54.83xvs Biotechnology peers
Gross Margin
53.96%vs Biotechnology peers
Profit Margin
7.65%vs Biotechnology peers
Operating Margin
-0.12%vs Biotechnology peers
Return on Assets (TTM)
0.33%vs Biotechnology peers
Return on Equity (TTM)
1.95%vs Biotechnology peers
Revenue (TTM)
432.55MCNY64.32M · vs all stocks (USD)
Revenue per Share (TTM)
6.38CNYUpdated Aug 21, 2026Quarterly Revenue Growth
13.00%vs Biotechnology peers
Gross Profit (TTM)
226.14MCNY33.63M · vs all stocks (USD)
EBITDA (TTM)
81.22MCNY12.08M · vs all stocks (USD)
Net Income (TTM)
33.09MCNY4.92M · vs all stocks (USD)
Operating Cash Flow (TTM)
88.29MCNY13.13M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
24.41MCNY3.63M · vs all stocks (USD)
Forward Annual Dividend Rate
0.1300CNYUpdated Aug 21, 2026Forward Annual Dividend Yield
0.30%vs all stocks
Trailing Annual Dividend Rate
0.1250CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.30%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
421.02MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
203.40MCNYFY2025 · Dec 31, 2025Gross Profit
217.62MCNYFY2025 · Dec 31, 2025Operating Income
24.80MCNY3.69M · vs all stocks (USD)
Pre-tax Income
29.10MCNYFY2025 · Dec 31, 2025Income Tax Expense
-2.34MCNYFY2025 · Dec 31, 2025Net Income
31.44MCNYFY2025 · Dec 31, 2025EBIT
31.52MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
81.22MCNYFY2025 · Dec 31, 2025Research & Development
86.69MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
14.08MCNYFY2025 · Dec 31, 2025Other Operating Expenses
2.70MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.58MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.42MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.4200CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.4200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
74.85MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
74.85MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
31.44MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
26.48MCNYFY2025 · Dec 31, 2025Free Cash Flow
-19.09MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
145.79MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
31.44MCNYFY2025 · Dec 31, 2025Other Non-cash Items
20.23MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-14.71MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-10.49MCNYFY2025 · Dec 31, 2025Capital Expenditures
-45.57MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.04BCNYFY2025 · Dec 31, 2025Sale of Investments
2.96BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-125.19MCNYFY2025 · Dec 31, 2025Other Financing Charges
-20.41MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-20.41MCNYFY2025 · Dec 31, 2025Shares Outstanding
77.96MSharesUpdated Aug 21, 2026Float Shares
28.82MSharesUpdated Aug 21, 2026% Held by Insiders
72.22%vs all stocks
% Held by Institutions
2.61%vs all stocks
Total Cash (MRQ)
931.99MCNY138.60M · vs all stocks (USD)
Total Cash per Share (MRQ)
12.32CNYUpdated Aug 21, 2026Total Debt (MRQ)
59.00MCNY8.77M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0345xvs Biotechnology peers
Current Ratio (MRQ)
5.83xvs Biotechnology peers
Book Value per Share (MRQ)
22.65CNYUpdated Aug 21, 2026Total Assets
1.98BCNY294.97M · vs all stocks (USD)
Total Current Assets
1.18BCNYFY2025 · Dec 31, 2025Total Liabilities
274.33MCNYFY2025 · Dec 31, 2025Total Non-current Assets
802.29MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
58.37MCNYFY2025 · Dec 31, 2025Total Current Liabilities
215.97MCNYFY2025 · Dec 31, 2025Cash
144.95MCNYFY2025 · Dec 31, 2025Cash Equivalents
5.44MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
150.39MCNYFY2025 · Dec 31, 2025Other Short-term Investments
883.15MCNYFY2025 · Dec 31, 2025Accounts Receivable
112.38MCNYFY2025 · Dec 31, 2025Inventory
18.72MCNYFY2025 · Dec 31, 2025Accounts Payable
61.28MCNYFY2025 · Dec 31, 2025Short-term Debt
15.74MCNYFY2025 · Dec 31, 2025Other Current Liabilities
192.15KCNYFY2025 · Dec 31, 2025Long-term Debt
41.08MCNYFY2025 · Dec 31, 2025Common Stock (Book)
77.96MCNYFY2025 · Dec 31, 2025Retained Earnings
108.78MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.71BCNY254.17M · vs all stocks (USD)
Treasury Stock
62.09MCNYFY2025 · Dec 31, 202552-Week Low
30.36CNYUpdated Aug 21, 202652-Week High
65.80CNYUpdated Aug 21, 202652-Week Change
-28.97%vs all stocks
Beta
0.3300xvs all stocks
50-Day MA
36.30CNYUpdated Aug 21, 2026200-Day MA
41.10CNYUpdated Aug 21, 2026Avg 10-Day Volume
4.87MSharesUpdated Aug 21, 2026Avg 30-Day Volume
2.53MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.4400CNYUpdated Aug 21, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Debt Falling While Share Count Rises
Debt has fallen for four years while the share count rose over eight.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.54Profit Margin: 0.08
Financial Health
Altman Z-Score 8.12: safe zoneNotable
Altman Z-Score: 8.12
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Ginkgo Bioworks Holdings Inc.
Tier 1ProductionApproval-Gated PipelineSenseMakingInterface
ClearPoint Neuro Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Eikon Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Hinova Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Avacta Group Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Clarity Pharmaceuticals Ltd
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
PureTech Health plc
Tier 1ProductionApproval-Gated PipelineRiskInterface
Evolus Inc.
Tier 1ProductionApproval-Gated PipelineAttentionInterface
Qurient Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Up-Shine Lighting Co., Ltd.
3 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityDebt Falling While Share Count RisesRevenue Growing With Receivables Growing
Shanghai MicroPort EP MedTech Co., Ltd.
3 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityDebt Falling While Share Count RisesMinimal Tax and Interest Drag
Zhubo Design Co. Ltd.
3 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityDebt Falling While Share Count RisesMinimal Tax and Interest Drag